XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $2M invested in XTL Biopharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
18% more capital invested
Capital invested by funds: $1.69M → $2M (+$306K)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$124 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 2 |
SW
SteelPeak Wealth
Woodland Hills,
California
|
-$9.3K |
| 3 |
Renaissance Technologies
New York
|
-$5.54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $794K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $794K | – | – | – |
|
|
3
Morgan Stanley
New York
| $216K | +$124 | +9 | +0.1% |
|
|
4
Renaissance Technologies
New York
| $148K | -$5.54K | -403 | -4% |
|
|
SW
5
SteelPeak Wealth
Woodland Hills,
California
| $47K | -$9.3K | -676 | -19% |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$12K | -881 | Closed |
|
XTLB Hedge Fund Activity: Q2 2021 in Review
5 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2021, worth a combined $2M — up 18% from $1.69M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $124. The largest seller was UBS Group, exiting entirely with an estimated $12K sold.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2021, down from 6 in Q1 2021.
- Funds reported $2M of XTL Biopharmaceuticals stock for Q2 2021, up 18% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q2 2021 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q2 2021 was Morgan Stanley, an estimated $124 added.
- The largest XTL Biopharmaceuticals seller in Q2 2021 was UBS Group, an estimated $12K sold.
Based on aggregated 13F filings for Q2 2021.